Cargando…

Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics

Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s, but the clinical indications for their use “at the age of biologics” remain to be assessed. From 2013 to 2017, 145 patients underwent a first treatment cycle with phototherapy. They...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Mariateresa, Damiani, Caterina, Arisi, Mariachiara, Tomasi, Cesare, Tonon, Francesco, Venturini, Marina, Calzavara-Pinton, Piergiacomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179382/
https://www.ncbi.nlm.nih.gov/pubmed/37176743
http://dx.doi.org/10.3390/jcm12093303
_version_ 1785041084724805632
author Rossi, Mariateresa
Damiani, Caterina
Arisi, Mariachiara
Tomasi, Cesare
Tonon, Francesco
Venturini, Marina
Calzavara-Pinton, Piergiacomo
author_facet Rossi, Mariateresa
Damiani, Caterina
Arisi, Mariachiara
Tomasi, Cesare
Tonon, Francesco
Venturini, Marina
Calzavara-Pinton, Piergiacomo
author_sort Rossi, Mariateresa
collection PubMed
description Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s, but the clinical indications for their use “at the age of biologics” remain to be assessed. From 2013 to 2017, 145 patients underwent a first treatment cycle with phototherapy. They achieved a median final EASI score of 9.90 with UVA1 and 13.70 with NB-UVB. The rates of patients achieving an IGA score of 0/1 persistent for at least 6 months were 33% with UVA1 and 28% with NB-UVB, and the rates with an EASI90 improvement were 10.9% with UVA1 and 11.0% with NB-UVB. The cut-off baseline EASI values for a good probability to achieve a 0/1 IGA were 24.4 with UVA1 and 24.7 with NB-UVB. A 0/1 IGA persistent for at least 6 months was more likely to be achieved by patients with a history of flares interspersed with periods of mild or no disease. From 2018, we only enrolled patients with the above-mentioned characteristics. The number of treated patients was lower, but the final EASI score, the rate of patients achieving IGA 0/1 persistent for at least 6 months, and EASI90 were significantly higher. Medium-dose UVA1 and NB-UVB phototherapies remain useful for the treatment of AD patients with a baseline EASI score lower than 24.4 and 24.7, respectively, and a medical history of flares followed by prolonged periods of complete or near-complete remission.
format Online
Article
Text
id pubmed-10179382
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101793822023-05-13 Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics Rossi, Mariateresa Damiani, Caterina Arisi, Mariachiara Tomasi, Cesare Tonon, Francesco Venturini, Marina Calzavara-Pinton, Piergiacomo J Clin Med Article Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s, but the clinical indications for their use “at the age of biologics” remain to be assessed. From 2013 to 2017, 145 patients underwent a first treatment cycle with phototherapy. They achieved a median final EASI score of 9.90 with UVA1 and 13.70 with NB-UVB. The rates of patients achieving an IGA score of 0/1 persistent for at least 6 months were 33% with UVA1 and 28% with NB-UVB, and the rates with an EASI90 improvement were 10.9% with UVA1 and 11.0% with NB-UVB. The cut-off baseline EASI values for a good probability to achieve a 0/1 IGA were 24.4 with UVA1 and 24.7 with NB-UVB. A 0/1 IGA persistent for at least 6 months was more likely to be achieved by patients with a history of flares interspersed with periods of mild or no disease. From 2018, we only enrolled patients with the above-mentioned characteristics. The number of treated patients was lower, but the final EASI score, the rate of patients achieving IGA 0/1 persistent for at least 6 months, and EASI90 were significantly higher. Medium-dose UVA1 and NB-UVB phototherapies remain useful for the treatment of AD patients with a baseline EASI score lower than 24.4 and 24.7, respectively, and a medical history of flares followed by prolonged periods of complete or near-complete remission. MDPI 2023-05-05 /pmc/articles/PMC10179382/ /pubmed/37176743 http://dx.doi.org/10.3390/jcm12093303 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rossi, Mariateresa
Damiani, Caterina
Arisi, Mariachiara
Tomasi, Cesare
Tonon, Francesco
Venturini, Marina
Calzavara-Pinton, Piergiacomo
Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics
title Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics
title_full Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics
title_fullStr Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics
title_full_unstemmed Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics
title_short Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics
title_sort definition of the clinical characteristics of patients with moderate and severe atopic dermatitis for whom narrow-band uvb (nb-uvb) and medium-dose uva1 phototherapies are still valuable treatment options at the age of biologics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179382/
https://www.ncbi.nlm.nih.gov/pubmed/37176743
http://dx.doi.org/10.3390/jcm12093303
work_keys_str_mv AT rossimariateresa definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics
AT damianicaterina definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics
AT arisimariachiara definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics
AT tomasicesare definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics
AT tononfrancesco definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics
AT venturinimarina definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics
AT calzavarapintonpiergiacomo definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics